SCHEMBL7708019

SCHEMBL7708019

CC1Oc2ccc(C(Cc3ccc(Cl)cc3Cl)NC(=O)OC(C)(C)C)cc2N=C1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 2/20 0.42
MC4R P32245 1/20 0.39
IDO1 P14902 2/20 0.37
ALDH1A1 P00352 5/20 0.37
HPGD P15428 3/20 0.37
KDM4E B2RXH2 3/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 2/20 0.36
GLA P06280 1/20 0.36
XBP1 P17861 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HDAC8 Q9BY41 3/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
GAA P10253 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7704992 0.91 ALDH1A1 (0.35) SMN1; SMN2TP53MC4RALDH1A1HPGD
SCHEMBL7704969 0.89 ALDH1A1 (0.36) SMN1; SMN2TP53ALDH1A1HPGDHTT
SCHEMBL7704904 0.87 CTSL (0.45) SMN1; SMN2TP53ALDH1A1HPGDKDM4E
SCHEMBL7711460 0.86 ALDH1A1 (0.34) SMN1; SMN2TP53ALDH1A1HPGDKDM4E
SCHEMBL7710869 0.84 CTSS (0.42) TP53ALDH1A1HPGDKDM4EHTT
SCHEMBL7704912 0.84 ALDH1A1 (0.45) SMN1; SMN2TP53ALDH1A1HPGDHTT
SCHEMBL7711369 0.84 ALDH1A1 (0.37) SMN1; SMN2TP53ALDH1A1HPGDKDM4E
SCHEMBL7713371 0.83 NPSR1 (0.37) SMN1; SMN2TP53ALDH1A1HPGDKDM4E
SCHEMBL7713363 0.83 HPGD (0.41) SMN1; SMN2TP53ALDH1A1HPGDKDM4E
SCHEMBL7708193 0.83 ALDH1A1 (0.38) SMN1; SMN2TP53ALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed